Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-Overloaded Patients with Sickle Cell Disease and Other Anemias

Mona Hamdy, Amal El-Beshlawy, Fatma Soliman Elsayed Ebeid, Janet L. Kwiatkowski, Julie Kanter, Baba PD Inusa, Suzan Williams, David Lee, Noemi T Temin, Caroline Fradette, Fernando Tricta, Mohsen Saleh Elalfy

Blood (2021) 138 (Supplement 1): 762.

https://doi.org/10.1182/blood-2021-148064

Published: 2021

Journal Articles

Safety and Efficacy of Early-Start Deferiprone in Infants and Young Children with Beta-Thalassemia (START study)

Mohsen Saleh Elalfy, Amal El-Beshlawy, Amira Adly, Fatma Soliman Elsayed Ebeid, Caroline Fradette, David Lee, Noemi T Temin, Fernando Tricta, Anna Rozova, Mona Hamdy

Blood (2021) 138 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2021-147595

Published: 2021

Journal Articles

A Prospective Randomized Multicenter Trial Using Either Deferiprone or Deferasirox after an Early Start of Deferiprone or Placebo in Young Children Newly Diagnosed with Transfusion-Dependent Beta-Thalassemia

Mohsen Saleh Elalfy, Amira Adly, Fatma Soliman Elsayed Ebeid, Amal El-Beshlawy, Neveen Salama, Mona Hamdy

Blood (2021) 138 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2021-149359

Published: 2021

Journal Articles

Largest Cohort Study of Gaucher Disease Type 3 from a Single Center in Egypt Spanning Two Decades

Amal El-Beshlawy, MD, Khaled Mohamed Abd El-Azim Eid, MD, Amina AbdelSalam, MD, Fadwa Said Mohamed, MD, Yasmeen M.M. Selim, Nadeen Gebril, Ekram Fateen, Pramod K. Mistry, MD PhD FRCP

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-141776

Published: 2020

Journal Articles

Three Distinct Groups of Phenotype Severity in Beta-Thalassemia

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139196

Published: 2020

Journal Articles

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Jo Howard, MBBChir, MRCP, FRCPath, Kenneth I. Ataga, MD, R. Clark Brown, MD PhD, Maureen Achebe, MD MPH, Videlis Nduba, MD, Amal El-Beshlawy, MD, Hoda Hassab, MD, Irene Agodoa, MD, Margaret Tonda, PharmD, Sarah Gray, PhD, Joshua Lehrer-Graiwer, MD MPhil, FACC, Elliott Vichinsky, MD

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-140553

Published: 2020

Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Blood (2019) 134 (Supplement_1): 618.

https://doi.org/10.1182/blood-2019-122062

Published: 2019

Journal Articles

Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients

Fernando Tricta, MD, Mariagrazia Felisi, PhD, Oscar Della Pasqua, Amal El-Beshlawy, MD, Hoda Hassab, MD, Antonis Kattamis, Manika Kreka, MD, Giorgio Reggiardo, Laila Metwally Sherief, MD, Michael Spino, PharmD, Bianca Tempesta, PhD, Yu-Chung Tsang, PhD, Adriana Ceci, MD

Blood (2019) 134 (Supplement_1): 3552.

https://doi.org/10.1182/blood-2019-127933

Published: 2019

Journal Articles

Development of a Severity Score System for Thalassemia Syndromes

Blood (2019) 134 (Supplement_1): 2225.

https://doi.org/10.1182/blood-2019-124675

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Amal El-Beshlawy, MD, Amina AbdelSalam, MD, Gamal Fathy, MD, Khaled M. Salamaa, MD, Mona El ghamrawy, MD, Samar S. Ramadan, M.Sc., Alaa M. Elhaddad, MD

Blood (2019) 134 (Supplement_1): 5732.

https://doi.org/10.1182/blood-2019-124398

Published: 2019

Journal Articles

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Flora Peyvandi, MD PhD, Paolo Bucciarelli, MD, Carla Valsecchi, BSc, Marco Boscarino, Roberta Palla, PhD, Elena Santagostino, Amal El-Beshlawy, Mohsen Saleh Elalfy, MD, Vijay M. Ramanan, MBBS,MDDM, Peyman Eshghi, MD, Suresh Hanagavadi, MD, Mehran Karimi, MD, Cecil Ross, MD, Mamta V Manglani, MD, Guy Young, Tulika Seth, MDMBBS,FAAP, Shashikant Apte, MD FRCPA, Dinesh M Nayak, MD, Maria Elisa Mancuso, Johnny Mahlangu, Bonanad Santiago, MD, Monica H Cerqueira, MD PhD, Nadia P Ewing, MD, Christoph Male, MD, Tarek Owaidah, MDFRCPA, Veronica Soto Arellano, MD, Suvankar Majumdar, MBCHB, Mindy Simpson, MD, Mathew Thomas, MD, Ezio Zanon, Marilyn J Manco-Johnson, MD, Monica Martinez, MD, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Rogelio Alejandro Paredes-Aguilera, MD, Alessandra N L Prezotti, MD MSc, Klaus Schmitt, MD, Bulent Zulfikar, Prof, Pier Mannuccio Mannucci, MD, Frits Richard Rosendaal, MD

Blood (2018) 132 (Supplement 1): 384.

https://doi.org/10.1182/blood-2018-99-114599

Published: 2018

Journal Articles

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Blood (2018) 132 (Supplement 1): 505.

https://doi.org/10.1182/blood-2018-99-118508

Published: 2018

Journal Articles

Non Invasive Evaluation of Hepatic Iron Concentration By Fibroscan in Transfusion-Dependent Egyptian Patients with Chronic Hemolytic Anemia

Amal El-Beshlawy, Dalia Omran, MD, Hala Mohsen Abdullatif, MD, Niveen Salama, MD, Mohamed Ahmed Abdel Naeem, MSc, Mona El ghamrawy, MD, Amina Abdel-Salam, MD

Blood (2018) 132 (Supplement 1): 1061.

https://doi.org/10.1182/blood-2018-99-118695

Published: 2018

Journal Articles

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy

Timothy M. Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas Andrew Burrow, Ana Maria Martins, Elena Lukina, Barry Rosenbloom, Ozlem Goker-Alpan, Nora Watman, Amal El-Beshlawy, Priya S. Kishnani, Maria Lucia Pedroso, Sebastiaan J. M. Gaemers, Regina Tayag, M. Judith Peterschmitt

Blood (2017) 129 (17): 2375–2383.

https://doi.org/10.1182/blood-2016-12-758409

Published: 2017

Journal Articles

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Elliott Vichinsky, Amal El-Beshlawy, Azzam Alzoebie, Annie Kamdem, MD, Suzanne Koussa, Thirachit Chotsampancharoen, Andreas Bruederle, Jackie Han, Mohsen Elalfy

Blood (2016) 128 (22): 2470.

https://doi.org/10.1182/blood.V128.22.2470.2470

Published: 2016

Journal Articles

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4831.

https://doi.org/10.1182/blood.V128.22.4831.4831

Published: 2016

Journal Articles

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy

Blood (2016) 128 (22): 4834.

https://doi.org/10.1182/blood.V128.22.4834.4834

Published: 2016

Journal Articles

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Flora Peyvandi, MD PhD, Pier Mannuccio Mannucci, MD, Isabella Garagiola, PhD, Mohsen Elalfy, MD, Amal El-Beshlawy, MD, Madatha V. Ramanan, MD, Peyman Eshghi, MD, Suresh Hanagavadi, Ramabadran Varadarajan, MD, Mehran Karimi, MD, Mamta V. Manglani, MD, Cecil Ross, MD, Guy Young, MD, Tulika Seth, MD, Shashikant Apte, MD FRCPA, Dinesh M. Nayak, MD, Adriana C. Sandoval Gonzales, MD, Elena Santagostino, MD PhD, Maria Elisa Mancuso, MD PhD, Johnny N. Mahlangu, MD, Santiago Bonanad, PhD, Monica Cerqueira, MD, Nadia P. Ewing, MD, Christoph Male, MD MSC, Tarek Owaidah, MD FRCPA, Veronica Soto Arellano, MD, Nathan L. Kobrinsky, MD FRCP, Suvankar Majumdar, MD, Rosario Perez Garrido, MD, Anupam Sachdeva, Mindy Simpson, MD FAAP, Mathew Thomas, Ezio Zanon, MD, ALI Bulent Antmen, Kaan Kavakli, MD, Marilyn Manco-Johnson, MD, Monica Martinez, MD, Esperanza Marzouka, MS, PS, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Angeles Palomo Bravo, MD, Rogelio Paredes Aguilera, MD, Alessandra Nunes Loureiro Prezotti, MD, Schmitt Klaus, MD, Brian M. Wicklund, MD MPH, Bulent Zulfikar, MD, Rosendaal R. Frits, MD PhD

Blood (2015) 126 (23): 5.

https://doi.org/10.1182/blood.V126.23.5.5

Published: 2015

Journal Articles

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Yesim Aydinok, Antonis Kattamis, M. Domenica Cappellini, Amal El-Beshlawy, Raffaella Origa, Mohsen Elalfy, Yurdanur Kilinç, Silverio Perrotta, Zeynep Karakas, Vip Viprakasit, Dany Habr, Niculae Constantinovici, Junwu Shen, John B. Porter

Blood (2015) 125 (25): 3868–3877.

https://doi.org/10.1182/blood-2014-07-586677

Published: 2015

Includes: Supplemental data

Journal Articles

Study of the Effect of HFE Gene Mutations on Iron Overload in Egyptian Thalassemia Patients

Amal El-Beshlawy, MD/Professor, Manal Michel Wilson, Professor, Elwakeel Hanan, Assistant Professor, Mona Elghmarwy, Professor, Fadwa Said, MD, Mary Assaad, MSc

Blood (2014) 124 (21): 1359.

https://doi.org/10.1182/blood.V124.21.1359.1359

Published: 2014

NARROW

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-Overloaded Patients with Sickle Cell Disease and Other Anemias

Safety and Efficacy of Early-Start Deferiprone in Infants and Young Children with Beta-Thalassemia (START study)

A Prospective Randomized Multicenter Trial Using Either Deferiprone or Deferasirox after an Early Start of Deferiprone or Placebo in Young Children Newly Diagnosed with Transfusion-Dependent Beta-Thalassemia

Largest Cohort Study of Gaucher Disease Type 3 from a Single Center in Egypt Spanning Two Decades

Three Distinct Groups of Phenotype Severity in Beta-Thalassemia

Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients

Development of a Severity Score System for Thalassemia Syndromes

Hematopoietic Stem Cell Transplantation in Βthalassemia Major: The Egyptian Outcome

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease

Non Invasive Evaluation of Hepatic Iron Concentration By Fibroscan in Transfusion-Dependent Egyptian Patients with Chronic Hemolytic Anemia

Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy

Long-Term Therapy with Deferasirox in Young Pediatric Patients with Transfusional Hemosiderosis Completing up to 5 Years of Treatment in the Observational E.N.T.R.U.S.T. Study

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Study of the Effect of HFE Gene Mutations on Iron Overload in Egyptian Thalassemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only